Lefamulin Acetate Patent Expiration
Lefamulin Acetate is used for treating community-acquired bacterial pneumonia in adults. It was first introduced by Nabriva Therapeutics Ireland Dac
Lefamulin Acetate Patents
Given below is the list of patents protecting Lefamulin Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xenleta | US9120727 | Process for the preparation of pleuromutilins | May 23, 2031 | Nabriva |
| Xenleta | US8071643 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | Jan 16, 2029 | Nabriva |
| Xenleta | US8153689 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | Mar 19, 2028 | Nabriva |
| Xenleta | US6753445 | Pleuromutilin derivatives having antibacterial activity |
Jul 09, 2021
(Expired) | Nabriva |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lefamulin Acetate's patents.
Latest Legal Activities on Lefamulin Acetate's Patents
Given below is the list recent legal activities going on the following patents of Lefamulin Acetate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 02 Oct, 2023 | US8153689 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 23 May, 2023 | US8071643 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 22 Feb, 2023 | US9120727 |
| Patent Term Extension Certificate Critical | 15 Feb, 2023 | US8071643 |
| Withdrawal of Application for PTE Critical | 14 Feb, 2023 | US9120727 |
| Withdrawal of Application for PTE Critical | 14 Feb, 2023 | US8153689 |
| Notice of Final Determination -Election Required | 05 Jan, 2023 | US8071643 |
| Notice of Final Determination -Election Required | 05 Jan, 2023 | US8153689 |
| Notice of Final Determination -Election Required | 05 Jan, 2023 | US9120727 |
| transaction for FDA Determination of Regulatory Review Period | 28 Sep, 2022 | US8071643 |
Lefamulin Acetate's Family Patents
